Metabolomics reveals distinct, antibody-independent, molecular signatures of MS, AQP4-antibody and MOG-antibody disease by Jurynczyk, Macieij et al.
1 
 
Metabolomics reveals distinct, antibody-independent, molecular signatures 
of MS, AQP4-antibody and MOG-antibody disease. 
Maciej Jurynczyk, MD, PhD*
1,2
, Fay Probert, PhD*
3
, Tianrong Yeo, MRCP
3,4
, George 
Tackley, MD
1
, Tim D.W. Claridge, DPhil
5
, Ana Cavey
1
, Mark R. Woodhall, PhD
1
, Siddharth 
Arora, DPhil
6
, Torsten Winkler, PhD
7
, Eric Schiffer, PhD
7
, Angela Vincent, FRCPath
1
, 
Gabriele DeLuca, MD, DPhil
1
, Nicola R. Sibson, PhD
8
, M. Isabel Leite, DPhil
1
, Patrick 
Waters, PhD
1
, Daniel C Anthony, PhD**
3
, and Jacqueline Palace, DM**
1
. 
*these authors contributed equally 
**these authors contributed equally  
 
1. Nuffield Department of Clinical Neurosciences, Level 3, West Wing, John Radcliffe Hospital, 
University of Oxford, Headley Way, Oxford OX3 9DU, UK. 
2. Department of Neurology, Medical University of Lodz, Lodz, Poland. 
3. Department of Pharmacology, University of Oxford, Mansfield Road, Oxford OX1 3QT, UK. 
4. Department of Neurology, National Neuroscience Institute, 11 Jalan Tan Tock Seng, Singapore 
308433, Singapore 
5. Chemistry Research Laboratory, Department of Chemistry, University of Oxford, Mansfield Road, 
Oxford OX1 3TA, UK. 
6. Mathematical Institute, University of Oxford, Woodstock Rd., Oxford, OX2 6GC, UK. 
7. numares AG, Am Biopark 9, 93053 Regensburg, Germany. 
8. Cancer Research UK & Medical Research Council Oxford Institute for Radiation Oncology, 
Department of Oncology, University of Oxford, Oxford, OX37DQ, UK. 
 
 
Correspondence to:  Dr Jacqueline Palace (clinical neurology), Neurosciences Offices, Level 3, West Wing, 
John Radcliffe Hospital, Headley Way, OX3 9DU Oxford, Tel: 01865 231900, Email: 
jacqueline.palace@ndcn.ox.ac.uk; or Dr Fay Probert (technical aspects/statistics), Department of Pharmacology, 
Mansfield Road, Oxford, OX1 3QT, Tel: +44(0)1865 281135, fay.probert@pharm.ox.ac.uk 
 
Key words: Multiple sclerosis, neuromyelitis optica, metabolomics, biomarker, MOG 
antibody disease 
 
 
 
 
 
 
2 
 
Abstract. 
The overlapping clinical features of relapsing remitting multiple sclerosis (RRMS), 
aquaporin-4 (AQP4)-antibody (Ab) neuromyelitis optica spectrum disorder (NMOSD), and 
myelin oligodendrocyte glycoprotein (MOG)-Ab disease mean that detection of disease 
specific serum antibodies is the gold standard in diagnostics. However, antibody levels are 
not prognostic and may become undetectable after treatment or during remission. Therefore, 
there is still a need to discover antibody-independent biomarkers. We sought to discover 
whether plasma metabolic profiling could provide biomarkers of these three diseases and 
explore if the metabolic differences are independent of antibody titre. Plasma samples from 
108 patients (34 RRMS, 54 AQP4-Ab NMOSD, and 20 MOG-Ab disease) were analysed by 
nuclear magnetic resonance spectroscopy followed by lipoprotein profiling. Orthogonal 
partial-least squares discriminatory analysis (OPLS-DA) was used to identify significant 
differences in the plasma metabolite concentrations and produce models (mathematical 
algorithms) capable of identifying these diseases. In all instances, the models were highly 
discriminatory, with a distinct metabolite pattern identified for each disease. In addition, 
OPLS-DA identified AQP4-Ab NMOSD patient samples with low/undetectable antibody 
levels with an accuracy of 92%.  The AQP4-Ab NMOSD metabolic profile was characterised 
by decreased levels of scyllo-inositol and small high density lipoprotein particles along with 
an increase in large low density lipoprotein particles relative to both RRMS and MOG-Ab 
disease. RRMS plasma exhibited increased histidine and glucose, along with decreased 
lactate, alanine, and large high density lipoproteins while MOG-Ab disease plasma was 
defined by increases in formate and leucine coupled with decreased myo-inositol. Despite 
overlap in clinical measures in these three diseases, the distinct plasma metabolic patterns 
support their distinct serological profiles and confirm that these conditions are indeed 
different at a molecular level. The metabolites identified provide a molecular signature of 
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each condition which is independent of antibody titre and EDSS, with potential use for 
disease monitoring and diagnosis.  
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Introduction. 
The field of central nervous system (CNS) inflammatory demyelinating diseases 
(IDD) has undergone considerable change with the discovery of antibodies against the 
aquaporin-4 water channel (AQP4-Ab) in neuromyelitis optica spectrum disorders (NMOSD) 
[30,31]. More recently, antibodies against conformational epitopes of the myelin 
oligodendrocyte glycoprotein (MOG) have been reported in AQP4-Ab negative NMOSD 
[28,35] as well as in pediatric acute disseminated encephalomyelitis (ADEM) [40]. The 
identification of these biomarkers, together with immunopathological studies, has led to their 
increasing recognition as distinct clinical entities separate from multiple sclerosis (MS) 
[25,53,34,52,46]. This has important prognostic and therapeutic implications, since it is now 
known that disability in AQP4-Ab NMOSD is wholly dependent on relapses and that MS-
specific treatments are not effective in reducing relapses in these patients [55,29,41]. 
There has been controversy as to whether CNS IDD associated with MOG-Ab 
represents a distinct condition separate from MS. Early on, MOG was proposed as a 
candidate autoantigen for MS and MOG is still routinely used as an immunogen in animal 
models of MS [6,1] including those used to explore the treatment mechanism of glatiramer 
acetate and fingolimod, both of which are approved drugs with proven efficacy in MS 
patients [45,10]. In addition, the specificity of MOG-Abs remained a concern as MOG-Abs 
were found in patients with other inflammatory diseases and in healthy controls [24,51]. 
Indeed, early studies revealed the presence of MOG-Ab in MS patients, however, these 
studies only detected antibodies against linear epitopes of MOG which were later found to 
not be clinically relevant [45]. Recent histopathology studies of patients with fully 
conformational MOG-Ab showed features compatible with pattern II MS pathology, 
reflecting humoral mediated mechanisms [42]. Observations of absent or very low levels of 
conformational MOG-Ab in MS patients, and reports of imaging features distinct from MS, 
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supports that MOG-Ab disease is a separate clinical entity from both MS and AQP4-Ab 
NMOSD, although pathological biomarkers have not been explored up to now [52,42,21,22]. 
MS is believed to be due to an aberrant T-cell response with B-cell mediated 
autoimmunity also playing a role [5], while autoantibodies are believed to be central to the 
pathogenesis of AQP4-Ab NMOSD [18], and MOG-Ab disease is now regarded as an 
antibody mediated condition. Despite these immunopathological differences, clinical features 
overlap which can make clinical distinction challenging [20]. RRMS, AQP4-Ab NMOSD, 
and MOG-Ab disease are all characterised by relapses which involve similar topographical 
regions within the CNS, interspersed with periods of remission. While several brain imaging 
studies have been able to distinguish MS from AQP4-Ab NMOSD or MOG-Ab disease, the 
almost identical presentation of the latter two conditions means distinction using radiological 
features alone is not possible [21,22]. Thus, while the underlying mechanisms appear to be 
unique, the molecular processes which lead to convergent, downstream histological and 
radiological signs remain unknown.  The absence of a biomarker for MS means that 
diagnosis is predicated on the exclusion of competing diagnoses and so, to date, reliable cell-
based assays detecting antibodies against AQP4 and MOG remain the gold standard for 
diagnosing and differentiating these three conditions. In spite of this, the most sensitive 
assays for these antibodies are not widely available and can still fail to detect the antibodies 
in patients with low antibody titre when treated and / or outside of relapses.  
Despite this invaluable role of AQP4 and MOG antibodies in diagnosis of CNS IDD, 
antibody titre does not appear to correlate with disease severity or predict relapses in the few 
published studies available [3,27,50,17]. This is particularly true for AQP4 NMOSD, though in 
MOG-Ab disease this is less clear. MOG-Ab seems to rapidly decline following monophasic 
ADEM and persist in chronic CNS demyelinating conditions [44]. The consistent observation 
for both conditions, however, is that the antibody titre can decrease with treatment or 
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when the disease is inactive, making the diagnosis in a small number of cases very 
problematic. Indeed, of the 54 AQP4-Ab NMOSD patients included in our study, 24 had low 
or undetectable antibody levels at the time of sample collection. Therefore, there is still a 
need for the discovery of antibody-independent biomarkers which would provide additional 
information on the molecular mechanisms underlying these diseases.  
High-resolution 
1
H nuclear magnetic resonance (NMR) spectroscopy is a non-
invasive tool, which, coupled with multivariate statistical analysis, identifies metabolite 
patterns in biofluid samples. We have previously shown that this technique is able to 
distinguish RRMS from healthy controls with 100% accuracy and from secondary 
progressive MS (SPMS) with an accuracy of 87% using the metabolite profile alone [7]. 
Here, using a similar approach, we present a comparison of the plasma metabolic profiles of 
patients with RRMS, AQP4-Ab NMOSD, and MOG-Ab disease, in an effort to uncover the 
metabolic signatures representative of each disease state. Their different metabolic profiles 
provide further evidence that these three diseases are indeed distinct, serving as potential 
diagnostic biomarkers which are independent of antibody levels and EDSS. The 
discriminatory metabolites identified also provide insight into the metabolic perturbations in 
each condition, allowing exploration of underlying pathophysiological mechanisms. 
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Methods. 
Patients. 
All patients included in the study were recruited from NMO and MS clinics in the John 
Radcliffe Hospital in Oxford.  Patients were diagnosed with AQP4-Ab or MOG-Ab disease if 
they had at least one clinically evident inflammatory demyelinating event and tested positive 
on cell-based assays for AQP4-Ab or MOG-Ab, respectively [52,53]. No patient was double 
positive for AQP4 and MOG Abs. AQP4-Ab end point titre was determined by the reciprocal 
of the highest positive serum dilution by cell-based assay. A fluorescence visual score of ≥ 1 
(range 0-4) was used as the threshold for positivity. Patients were diagnosed with RRMS if 
they fulfilled the revised 2010 McDonald criteria [43]. All patients gave their written consent 
to participate in the study (Oxford Research Ethics Committee C Ref: 10/H0606/56 
and 16/SC/0224). Patient demographics are shown in Table 1. 
 
Plasma sample collection. 
Blood was collected into vacutainer lithium-heparin tubes (Becton Dickinson, product 
number 367375) and stored at room temperature for 30 mins before centrifugation at 2,200 x 
g for 10 mins. Plasma was immediately aliquoted and stored at -80⁰C.  
 
NMR sample preparation.  
Plasma samples were defrosted at room temperature and centrifuged at 100,000 x g for 30 
minutes at 4C. 150 μL of the plasma supernatant was then diluted with 450 μL of 75 mM 
sodium phosphate buffer prepared in D2O (pH 7.4). Samples were then centrifuged at 16,000 
x g for 3 minutes to remove any precipitate before transferring to a 5-mm NMR tube. 
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NMR spectroscopy. 
All NMR spectra were acquired using a 700-MHz Bruker AVII spectrometer operating at 
16.4 T equipped with a 
1
H (
13
C/
15
N) TCI cryoprobe. Sample temperature was stable at 310K. 
1
H NMR spectra were acquired using a 1D NOESY presaturation scheme for attenuation of 
the water resonance with a 2 s presaturation. A spin-echo Carr-Purcell-Meiboom-Gill 
(CPMG) sequence with a τ interval of 400 μs, 80 loops, 32 data collections, an acquisition 
time of 1.5 s, a relaxation delay of 2 s, and a fixed receiver gain was used to supress broad 
signals arising from large molecular weight plasma components. CPMG spectra provide a 
measurement of small molecular weight metabolites and mobile side chains of lipoproteins in 
the plasma sample and were used for all further analysis. Due to their large molecular weight, 
AQP4 and MOG-IgG antibody resonances are not observed in the 
1
H CPMG spectra. 
1
H 
correlation spectroscopy (COSY) spectra were acquired on at least one sample in each 
classification to aid in metabolite identification. For quality control, pooled plasma samples 
were spread throughout the run to monitor technical variation. 
 
NMR data preprocessing. 
Resulting free induction decays (FIDs) were zero-filled by a factor of 2 and multiplied by an 
exponential function corresponding to 0.30 Hz line broadening prior to Fourier 
transformation. All spectra were phased, baseline corrected (using a 3
rd
 degree polynomial), 
and chemical shifts referenced to the lactate-CH3 doublet resonance at δ = 1.33 ppm in 
Topspin 2.1 (Bruker, Germany). Spectra were visually examined for errors in baseline 
correction, referencing, spectral distortion, or contamination and then exported to ACD/Labs 
Spectrus Processor Academic Edition 12.01 (Advanced Chemistry Development, Inc.). The 
regions of the spectra between 0.08 – 4.20 ppm and 5.20 – 8.50 ppm were divided in to 0.02 
ppm width ‘buckets’ and the absolute value of the integral of each spectral bucket was Pareto 
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scaled. Resonances were assigned by reference to literature values [47,32] and the Human 
Metabolome Database [58,57,56] and further confirmed by inspection of the 2D spectra, 
spiking of known compounds, and 1D-TOCSY spectra.  
 
Statistical analysis. 
The bucket integrals were imported into R software (R foundation for statistical computing, 
Vienna, Austria) [48]. All multivariate analysis was carried out using in-house R scripts and 
the ropls package [49]. Principal component analysis (PCA) was used to visualize the degree 
of separation between the disease classifications and detect potential outliers.  
OPLS-DA was employed to investigate differences in the disease classifications using 
the scheme outlined in Fig. 1. The quality of classification was assessed by first correcting for 
unequal class sizes and then splitting the data into a training set (90%) used to build the 
model which is then tested on the remaining 10% of the data. This process was repeated to 
produce 1000 models in total. If these models perform better than models produced by 
random class assignments this ensures that the separation observed between the groups is 
valid. A final model is produced using all of the data and a completely independent set of 
samples (n = 10) is used to determine the predictive value of this model. A schematic of the 
statistical approach can be found in supplementary Fig. 1. For a more detailed explanation of 
the analysis methods see the electronic supplementary material. 
 
Lipoprotein subclass quantification. 
To interrogate the lipoprotein subclasses in more detail and obtain fully quantitative values 
the AXINON
®
 lipoFIT
®
 system (numares AG, Germany) was used. This test system 
deconvolutes the broad methyl lipoprotein resonance into its constituent parts allowing the 
direct measurement of the cholesterol content, number of particles, and mean particle 
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diameter of each lipoprotein subpopulation. Lipoprotein groups measured include very low 
density lipoprotein (VLDL), low density lipoprotein (LDL), intermediate density lipoproteins 
(IDL), and high density lipoprotein (HDL) with each group further divided in to large and 
small subpopulations.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11 
 
Results. 
Patients and potential confounders. 
NMR spectra from 108 patients (34 RRMS, 54 AQP4-Ab NMOSD, and 20 MOG-Ab 
disease) were included in this study (Fig. 1) to determine whether we could generate model 
algorithms that could accurately distinguish between plasma samples from patients with 
RRMS, AQP4-Ab NMOSD or MOG-Ab disease. Demographic and clinical data, including 
treatment regimes, for the patients in each group were collected (Table 1). No significant 
differences were observed in any of the parameters recorded between AQP4-Ab NMOSD 
samples with high titre (≥ 200) (n = 30) and low titre/negative samples (< 200) (n = 24).  
Consistent with previous clinical reports, the majority of RRMS and AQP4-Ab 
patients were female (74% in the RRMS cohort and 85% in the AQP4-Ab NMOSD cohort) 
and the mean age of the AQP4-Ab NMOSD patients was higher (53 years in AQP4-Ab 
NMOSD compared to 41 and 39 in RRMS and MOG-Ab disease respectively) as a result of 
older age of onset in this condition. No significant differences or correlations were observed 
in any of the NMR data as a result of differences in the parameters described in Table 1, and 
multivariate analysis was unable to discriminate between the NMR spectra based on any of 
the factors recorded. Furthermore, the inclusion of gender, age, disease duration, time since 
relapse, or medication as variables in the multivariate analysis did not improve the OPLS-DA 
models, confirming that the differences in the parameters in Table 1 are not responsible for 
the discrimination between the three disease groups reported below. It was noted that the 
majority of AQP4-Ab NMOSD patients were on immunosuppression, whilst the majority of 
RRMS patients were on DMTs. Therefore, the effect of each medication (listed in Table 1) 
on the metabolic profile was investigated in greater detail. In all cases, multivariate analysis 
was unable to discriminate patients on therapy versus those not on the therapy. For example, 
we were unable to build models to discriminate AQP4-Ab NMOSD plasma treated with 
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steroids from those not treated with steroids. Importantly, RRMS and AQP4-Ab NMOSD 
patients not treated with steroids could still be distinguished from each other with high 
accuracy (Supplementary Fig. 2). This was the case for all medications listed in Table 1 
including disease modifying therapies (DMTs). Taken together, these findings suggest that 
none of the demographic and clinical parameters described in Table 1 had an appreciable 
effect on the metabolic profile.  
 
The NMR metabolite signature of RRMS plasma is distinct from AQP4-Ab NMOSD 
plasma. 
Simultaneous measurement of multiple metabolites in plasma using 
1
H-NMR 
spectroscopy followed by the application of multivariate analysis (OPLS-DA) to generate 
predictive models (mathematical algorithms) was employed here to build models to 
discriminate between RRMS (n = 29) and AQP4-Ab NMOSD plasma with titre ≥ 200 (n = 
25) at time of sampling. This subset was selected as it represents a diagnostically robust 
group of AQP4-Ab NMOSD patients suitable for model building.  Inspection of the resulting 
OPLS-DA scores plot (Fig. 2a) revealed a significant difference in the NMR metabolic 
pattern of RRMS plasma compared to that of AQP4-Ab NMOSD patients with titre ≥ 200 at 
time of sampling (Fig. 3). Each point in the scores plot represents an NMR spectrum from a 
single patient while the axis represents variation in the metabolite profile; the metabolite 
pattern of points lying close together in the plot are similar. The distinct clusters observed 
for AQP4-Ab NMOSD or RRMS suggests the presence of a distinct metabolic profile for 
each condition. In order to confirm that this separation had not occurred by chance, and that 
the OPLS-DA model produced is predictive of RRMS/AQP4-Ab NMOSD status, a 10-fold 
cross validation scheme with repetition was employed as described in detail in the electronic 
supplementary material. This approach validates the observed separation by creating an 
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ensemble of OPLS-DA models from randomly selected (size-matched) subsets of the data. 
Each model was then tested on an independent subset of the samples (excluded from the 
training set) in order to establish the accuracy of the ensemble of models. The same approach 
was applied to a random set of data, produced by random class assignment of the NMR 
dataset, and the ensemble accuracies are compared. Fig. 2b illustrates that the accuracy of the 
RRMS vs. APQ4-Ab NMOSD ensemble is significantly greater than that achieved by random 
chance and, in a rigorous manner, validates the separation observed and confirms that the 
metabolic signatures of these two diseases are distinct. 
Investigation of the variables responsible for the separation in the models revealed 
several metabolites with significant perturbations. Scyllo-inositol, histidine, glucose, and a 
subset of small lipoprotein particles were significantly increased in RRMS plasma whilst 
lactate, alanine, and a subset of large lipoprotein particles were significantly decreased 
relative to AQP4-Ab NMOSD plasma. 
As the above analysis proved that the discrimination between diseases did not occur 
by chance, it was valid to use the identified metabolites to predict disease classification. In 
order to further investigate the utility of the metabolites described and to produce a single 
algorithm for testing additional plasma samples, a single OPLS-DA model was produced 
using RRMS (n = 29) and high titre (≥200) AQP4-Ab NMOSD (n = 25) plasma NMR spectra 
validated above. This model was then tested with plasma samples from a randomly selected 
set of 10 entirely independent patients (5 with RRMS and 5 with AQP4-Ab NMOSD titres 
≥200), i.e. these naïve samples were not used in the model validation at any stage. This final 
model correctly predicted the disease classes of this independent test set with an accuracy of 
100% (Fig. 4a), confirming that the OPLS-DA model is able to identify AQP4-Ab NMOSD 
and RRMS using the NMR metabolite profile alone. 
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The NMR metabolic profile identifies AQP4-Ab NMOSD and RRMS in a manner 
independent of antibody titre. 
We next investigated whether the metabolite profile could identify AQP4-Ab 
NMOSD patient samples with titre < 200 or that were undetectable at the time of sampling (n 
= 24). All patients in this ‘low titre’ cohort had previously robust antibody titre results and a 
confirmed diagnosis of AQP4-Ab NMOSD. NMR spectra from AQP4-Ab NMOSD plasma 
with [100 ≤ titre < 200] (Fig. 4b), [20 ≤ titre < 100], (Fig. 4c), and negative results (Fig. 4d) 
at the time of sample collection were assessed using the OPLS-DA model generated above 
for AQP4-Ab NMOSD vs. RRMS. Of the 24 samples in this subset only two (one with a titre 
of 100 and one with a titre of 50) were incorrectly identified as RRMS by the OPLS-DA 
model, resulting in an accuracy of 92%. This finding indicates that the algorithm can identify 
AQP4-Ab NMOSD independent of antibody titre. Indeed, all of the AQP4-Ab NMOSD 
patients investigated whose antibody levels had become undetectable were correctly 
identified and no significant correlations or clustering on principle component analysis 
(Supplementary Fig. 3) were observed between any of the NMR metabolites measured and 
antibody titre. The same methods were used to investigate the effect of EDSS on the 
metabolite profile. We were unable to build models to discriminate between high and low 
EDSS patients and no clustering in the scores plots was observed (Supplementary Fig. 4). No 
significant differences were observed between the metabolite concentrations of the high and 
low AQP4-Ab titre samples and so these cohorts were combined into a single AQP4-Ab 
NMOSD (n = 54) cohort for all further analysis. 
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The plasma NMR metabolic profile of MOG-Ab disease is distinct from both RRMS 
and AQP4-Ab NMOSD. 
OPLS-DA was able to discriminate between the plasma metabolic profiles of MOG-
Ab disease and RRMS (Fig. 5a) and of MOG-Ab disease and AQP4-Ab NMOSD (Fig. 5b) 
with accuracies of 73 ± 4% and 73 ± 7% respectively. Once again, the accuracy of the 
ensemble of models was significantly greater than the null distribution (random chance 
models) validating the models and confirming that there are significant differences in the 
metabolic profiles of these three diseases. Interrogation of the discriminatory metabolites 
selected by the models revealed that the concentration of formate and leucine was increased 
in MOG-Ab plasma relative to both AQP4-Ab NMOSD and RRMS whilst the concentration 
of myo-inositol was decreased.  A summary of the significant plasma metabolite changes is 
given in Table 2; a unique set of metabolites was found to vary significantly for each disease 
class relative to both other diseases illustrating that the plasma metabolite profiles of these 
three diseases are distinct. Quantitative titre information is not obtained from the MOG-Ab 
assay employed. Nevertheless, no correlation was observed between the metabolic profile 
and the semi-quantitative fluorescence visual score (Supplementary Fig. 5). 
 
Lipoprotein profiling reveals perturbations to plasma lipoprotein populations in 
AQP4-Ab NMOSD and RRMS. 
Lipoproteins were identified as highly discriminatory; the removal of lipoprotein 
measurements resulted in a marked decrease in model accuracy. However, the standard 
metabolomics NMR experiment (
1
H CPMG) is unable to categorize individual lipoprotein 
subpopulations, measure lipoprotein particle number, size, or cholesterol concentration. As a 
result, we investigated the plasma lipoproteins with an NMR-based lipidomics platform to 
define which lipoprotein subpopulations in RRMS plasma were different from those in 
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AQP4-Ab NMOSD (Fig. 6). The number of large LDL and large HDL particles was 
significantly increased in AQP4-Ab NMOSD when compared with RRMS while the number 
of small HDL particles was significantly lower. As a consequence, an increase in the mean 
size of the HDL particles and an increase in the concentration of cholesterol in the subset of 
large HDL particles in AQP4-Ab NMOSD were also observed. Interestingly, no significant 
differences were observed in the total number of HDL particles or total HDL-cholesterol 
concentration between these diseases indicating that discrimination between these diseases 
would not be possible using a standard cholesterol test panel. All values obtained from this 
lipoFIT
® 
analysis matched the intensities obtained from the CPMG NMR spectra further 
validating the significant differences in the metabolites identified by the multivariate analysis. 
 
Discussion. 
In this study, using 
1
H NMR spectroscopy, we demonstrate that RRMS, AQP4-Ab 
NMOSD, and MOG-Ab disease display distinct plasma metabolite patterns. In the case of 
AQP4-Ab NMOSD, the discriminatory metabolite pattern identified is independent of 
antibody titre. The most significant differences in metabolite concentrations observed across 
the three conditions included changes in plasma lipoprotein and amino acid levels along with 
changes in scyllo-inositol and myo-inositol. In particular, MOG-Ab disease which overlaps 
with AQP4-Ab NMOSD both clinically and in treatment response, was associated with 
unique changes in the levels of formate, leucine, and myo-inositol, allowing distinction from 
both RRMS and AQP4-Ab NMOSD. This separation between MOG-Ab disease and AQP4-
Ab NMOSD has not been achieved by conventional MRI [21]. Thus, our observations 
contribute to the growing body of evidence that suggests that MOG-Ab disease represents a 
distinct clinical and pathophysiological entity. Since the metabolic profiles of MOG-Ab 
disease and AQP4-Ab NMOSD are different, despite them being predominantly humorally 
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mediated conditions, their individual separation from RRMS is not simply a result of an up-
regulated humoral immune response. Further investigation into the discriminatory 
metabolites could provide valuable information on the divergent pathophysiological 
processes underpinning each condition and their associated metabolic perturbations. 
However, the absence of direct histopathological correlates remains a limitation here as we 
cannot easily determine whether the magnitude of the responses is proportional to the CNS 
disease burden. 
Different distributions of lipoprotein populations were observed in AQP4-Ab 
NMOSD and RRMS, small HDL was decreased and large LDL was increased in AQP4-Ab 
NMOSD relative to both RRMS and MOG-ab disease, while large HDL was decreased in 
RRMS relative to AQP4-Ab NMOSD. Total HDL and LDL particle number did not change 
significantly across the diseases suggesting that the lipoprotein subclasses have been 
modified while overall lipoprotein particle numbers remain the same. This is supported by the 
fact that no significant differences were observed in total cholesterol, LDL-cholesterol, HDL-
cholesterol, or triglyceride concentrations and clarifies why a standard lipid panel is unable to 
discriminate between these three diseases. The lipoprotein population in AQP4-Ab NMOSD 
plasma is skewed towards larger particles while in RRMS plasma the lipoprotein particles are 
smaller. Our previous metabolomics study showed that RRMS serum has increased 
phosphocholine along with decreased β-hydroxybutyrate, and lipoprotein triacylglycerol (-
CH3, -(CH2-)n, and –CH2CH2CO) concentrations with respect to SPMS patient serum [7]. In 
addition, a recent report demonstrated that RRMS serum LDL particles were smaller in 
RRMS compared to both SPMS and control samples [19], further supporting that lipoprotein 
populations are perturbed in MS. Indeed, altered lipid profiles have been previously linked 
with disease activity and progression in MS patients [54] although data on lipid alterations in 
non-MS CNS inflammatory diseases are lacking. In one of the few studies investigating 
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lipoproteins in AQP4-Ab NMOSD patients, higher serum Apolipoprotein B levels were 
observed when compared with RRMS [33]. To the best of our knowledge, ours is the first 
study to compare plasma lipoprotein subclass data in RRMS, AQP4-Ab NMOSD, and MOG-
Ab disease in detail. 
The primary role of lipoprotein particles is the transport of lipid and other 
hydrophobic molecules around the body. Thus, lipoproteins are involved in a wide array of 
physiological processes including cell signaling, lipid homeostasis, and the acute phase 
response [23,8,14]. Previous studies have suggested that HDL particles are capable of 
crossing the blood brain barrier [12] and that LDL is present in the parenchyma of early MS 
lesions [39]. Lipoprotein modifications also occur in response to inflammation [2,38]. 
Therefore, it is plausible that the plasma lipoprotein perturbations observed here are the result 
of lipoprotein modifications in response to CNS injury and the inflammatory response. 
Alternatively, changes in lipoproteins may reflect altered energy metabolism in these 
patients. Indeed, the plasma glucose concentration was higher in AQP4-Ab NMOSD and 
lactate decreased in RRMS plasma. Metabolomics analysis has previously revealed decreased 
lactate levels in cerebral spinal fluid of RRMS patients compared to AQP4-Ab NMOSD 
although no significant difference in glucose was observed in this biofluid [26]. 
Myo-inositol was previously reported to be low within spinal cord lesions in a group 
of 5 NMOSD patients (2 AQP4-Ab positive and 3 negative) [4] and elevated white matter 
myo-insoitol has been linked with multiple sclerosis [11]. Interestingly, the OPLS-DA model 
revealed that myo-inositol was higher in both AQP4-Ab NMOSD and RRMS relative to 
MOG-Ab disease. Serum scyllo-inositol concentration has been shown previously to be 
decreased in 73% of a heterogeneous population of NMOSD patients (both AQP4-Ab 
positive and negative) when compared with RRMS [37]. This is consistent with our 
observation that scyllo-inositol is decreased in AQP4-Ab NMOSD relative to both RRMS 
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and MOG-Ab disease. Inositol phosphate and myo-inositol are components of myelin, and 
have roles in neural function and homeostasis in the CNS [36,16,13] and so the plasma myo-
inositol and scyllo-inositol concentrations may reflect perturbations in inositol phosphate 
metabolism as a result of demyelination. Taken together, the set of metabolic perturbations 
identified may reflect alterations in lipid transport, membrane breakdown, and energy 
metabolism.  
The data presented demonstrates that, in the case of AQP4-Ab NMOSD, the 
metabolite profile is independent of antibody titre. The OPLS-DA model was able to 
correctly identify AQP4-Ab NMOSD samples with antibody titres < 200 at the time of 
sampling with an accuracy of 92%, whilst high titre (≥ 200) AQP4-Ab NMOSD samples and 
RRMS samples were discriminated with 100% accuracy. This finding suggests that the 
metabolic profile could be diagnostically useful in cases of suspected AQP4-Ab NMOSD 
where antibody level has decreased or become undetectable over time with treatment. 
Patients in the acute setting are often treated empirically and the rarer diagnosis of NMOSD 
is usually addressed downstream. Thus, metabolic profiling may be particularly useful in 
cases where samples are taken after established immunosuppression and / or outside of onset 
of relapse. Whilst this may only be the case in a small number of individuals, we believe it is 
particularly noteworthy as, out of the 54 AQP4-Ab NMOSD patients (randomly sampled 
from the Oxford NMO clinic) included in this study, 7%  (n = 4) were seronegative at the 
time of sampling. Nevertheless, the samples from these four patients were correctly identified 
as AQP4-Ab NMOSD by the OPLS-DA model.  We explored whether this observation is 
also true of MOG-Ab disease. However, due to the lower incidence of this condition, only 
two samples from patients who were seronegative at time of sampling were available for 
analysis. Whilst both of these samples were correctly identified as MOG-Ab disease by the 
OPLS-DA model (data not shown), future work on a larger cohort will confirm whether the 
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metabolic profile is independent of MOG-Ab serostatus at sampling time-point. Given that 
the current work suggests that the AQP4-Ab NMOSD metabolic profile is independent of 
antibody titre, and that observational studies have reported that titres are not predictive of 
relapses, future work will explore the role of the discriminatory metabolites as biomarkers of 
disease activity.  
Differences were observed in some of the patient demographics between disease 
groups which were consistent with previous clinical reports and are in keeping with known 
differences in the demographics of these conditions. Most notably, significant differences in 
medication and gender ratio were observed. All potential confounding factors were assessed 
in detail and none of the parameters listed in Table 1 were found to have a significant impact 
on the metabolite concentrations measured. Addition of these parameters as variables in the 
OPLS-DA model did not improve accuracy confirming that the separation observed between 
the diseases was not due to any differences in patient demographics. In particular, we 
investigated the effect of steroid treatment on the metabolic profile due to the high proportion 
of AQP4-Ab NMOSD and MOG-Ab disease patients treated with steroids compared to 
RRMS. OPLS-DA was unable to discriminate between steroid-treated and steroid-untreated 
AQP4-Ab NMOSD patients, whilst the models separating AQP4-Ab NMOSD without 
steroid treatment and RRMS patients (none of which were on steroids) were still predictive. 
Steroid treatment is known to alter the lipoprotein profile, with the primary effect of 
prednisolone being an increase in total LDL cholesterol concentration [9]. However, total 
LDL cholesterol concentration was not found to be significantly altered between the AQP4-
Ab/RRMS/MOG-Ab samples tested. The same approach was used for every treatment 
(including DMTs) listed in Table 1 and no treatment had a significant effect on the strength 
of the models. We also demonstrated that EDSS does not impact the metabolite profiles of 
these three diseases and does not drive the discriminatory models produced (Supplementary 
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Fig. 4) confirming that the biomarkers identified are independent of EDSS and instead 
represent the underlying pathology. 
In conclusion, in this study we report unique plasma metabolite profiles in RRMS, 
AQP4-Ab NMOSD and MOG-Ab disease, and demonstrate that they differ significantly from 
each other, allowing for a highly predictive discrimination of these three diseases. The 
plasma metabolites underlying the separations were linked with lipoprotein populations, 
amino acids, glucose, lactate, formate, myo-inositol, and scyllo-inositol and may reflect 
metabolite pathway changes induced by demyelination, inflammation, blood brain barrier 
breakdown, and disruptions to energy metabolism. Our findings also show that the plasma 
NMR metabolic profile is capable of discriminating AQP4-Ab NMOSD from RRMS 
independently of antibody titre. Future work will examine whether the models developed in 
this study can be applied to childhood forms of demyelinating disease (in which MOG-Abs 
are commonly detected [15]), aid classification of heterogeneous cohorts such as antibody-
negative NMOSD and atypical MS, and whether the discriminatory metabolites can be 
utilized as biomarkers for disease activity.   
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Tables 
Table 1. Patient information. The Kolmogorov-Smirnov test was used to identify significant 
differences of each class compared to RRMS (*), AQP4-Ab NMOSD (~), or MOG-Ab disease (†) 
 
 
RRMS 
AQP4-Ab 
NMOSD 
MOG-Ab 
Number of patients 34 54 20 
Age, mean (range), y 41 (18 - 60) 53 (22 - 83)*† 39 (16 - 70) 
Gender, No. female (% female) 25 (74) 46 (85) 9 (45) 
EDSS, median (range) 4 (0-7) 3 (0 - 8) 2 (0 - 8) 
Disease duration, median (range), months 89 (1-301) 70 (3-270) 16 (1-420)*~ 
Time since relapse, median (range), months 23 (0 - 133) 22 (0-108) 8 (1-39)*~ 
On oral prednisolone, % 0% 85% 35% 
On prednisolone, mean dose mg 0 12 14 
On azathioprine, % 0 49 5 
On methotrexate, % 0 11 5 
On mycophenolate, %  0 19 5 
On interferon β, % 15 0 5 
On glatiramer, % 12 0 0 
On fingolimod, % 12 0 0 
On dimethyl fumarate, % 12 3 0 
On natalizumab, % 15 0 0 
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Table 2. Significant differences in the plasma metabolites of AQP4-Ab NMOSD, RRMS, and MOG-Ab 
disease. Increases and decreases relative to the other two disease classifications are indicated with ↑ and 
↓ respectively. Metabolites listed were identified as discriminatory by OPLS-DA 
 
 
AQP4-Ab NMOSD RRMS MOG-Ab 
Concentration of large LDL particles ↑ 
  
Size of HDL particles ↑ 
  
Glucose ↑   
Cholesterol concentration in large HDL (subclass A) ↑ 
  
Large LDL particles ↑   
Small HDL particles ↓ 
  
Phosphocholine/lipoprotein  ↓ 
  
Scyllo-inositol  ↓ 
  
Lysine/creatinine/creatine  
 
↑ 
 
Histidine  
 
↑ 
 
Large HDL particles 
 
↓ 
 
Lactate  
 
↓ 
 
Unsaturated lipid  
 
↓ 
 
Alanine 
 
↓ 
 
Formate  
  
↑ 
Leucine 
  
↑ 
Myo-inositol  
  
↓ 
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Figure Legends. 
Fig. 1 Illustration of the multivariate analysis methodology employed in this study.  
 
Fig. 2 a) OPLS-DA scores plot of RRMS (black) and AQP4-Ab NMOSD with titre ≥ 200 (red) 
NMR spectra. b) OPLS-DA model validation. The accuracy of the ensemble of 1000 RRMS V. 
AQP4-Ab NMOSD models, as determined by classification of an independent test set, is 
significantly greater than that of random data. Kolmogorov-Smirnov test p-values < 0.001 
are represented by *** 
 
Fig. 3 Average 1H CPMG spectra of RRMS (black), AQP4-Ab NMOSD (red), and MOG-Ab 
(yellow) plasma samples. Box plots illustrate significant differences in the NMR spectral 
integrals for a selection of metabolites selected by the OPLS-DA models. One-way ANOVA 
with post-hoc (Fisher’s LSD) p-values less than 0.05, 0.01, and 0.001 are represented by *, 
**, and *** respectively 
 
Fig. 4 Predictive OPLS-DA model for the discrimination of RRMS and AQP4-Ab NMOSD 
plasma. OPLS-DA scores plots of RRMS (black circle) and AQP4-Ab NMOSD (red circle) and 
predicted classifications of a) independent test set of RRMS (black square) and AQP4-Ab 
NMOSD (red square), b) low titre (≥100 and <200) AQP4-Ab NMOSD (yellow square)  c) very 
low titre (<100) AQP4-Ab NMOSD (blue square), and d) negative titre AQP4-Ab NMOSD 
(green square) plasma samples 
 
Fig. 5 Statistically significant OPLS-DA models for the separation of MOG-Ab (yellow) from a) 
RRMS (black) and b) AQP4-Ab NMOSD (red). Model validity was assessed by comparing the 
accuracy, sensitivity, and specificity of the ensemble with that of a null distribution using the 
Kolmogorov-Smirnov test (p-values<0.001 are indicated by ***) 
 
Fig. 6 LipoFIT variables with significant differences between groups AQP4-Ab NMOSD (red), 
RRMS (black), and MOG-Ab (yellow) following one-way ANOVA. Post-hoc (Fisher’s LSD) p-
values less than 0.05, 0.01, and 0.001 are represented by *, **, and *** respectively. LLDL-p, 
large low density lipoprotein particle concentration; LHDL-p, large high density lipoprotein 
particle concentration; SHDL-p, small high density lipoprotein particle concentration; HDL.A-
c, large high density lipoprotein cholesterol concentration 
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Detailed statistical methods. 
Stage 1. Model validation 
OPLS-DA was employed to investigate differences in the disease classifications using 
the schemes outlined in Fig. 1 and Fig. 2. OPLS-DA models were optimized by internal 7-fold 
cross-validation. The quality of classification was assessed using a 10-fold external cross-
validation scheme with 1000 repetitions in total, correcting for unequal class sizes. This 
validation scheme involves multiple iterations of splitting the data into training and testing sets, 
which ensures that any discrimination observed in the models cannot have occurred by chance. 
The training data is used to estimate the model parameters and learn the underlying 
discriminatory patterns between the groups under consideration, whereas the independent test 
set is employed to assess the accuracy and generalizability of the trained models in the 
ensemble (Fig. 1).  We quantified the outcome of the cross validation by calculating the 
accuracy, sensitivity, and specificity of each model (n = 1000) from the predicted 
classifications of the external independent test set, which was not used to build each model. It 
is important to appreciate that the classifier (OPLS-DA) was blinded to each test set when 
training each model. This validation scheme tends to avoid over-fitting and helps assess the 
generalizability of the model to previously unseen datasets. For an exhaustive discussion on 
validation of this approach see Arlot and Celisse (2010). These values were compared with 
those of a null distribution (obtained from randomly permuting the classifications) using the 
two-sided Kolmogorov-Smirnov test (significant if p-value 0.05 or less). 
Stage 2. Prediction and identification of discriminatory metabolites. 
If stage 1 of the analysis reveals that the OPLS-DA classifier performs significantly 
better than chance, the separation observed between classes is confirmed and it is valid to 
interrogate metabolites driving the separation and to use the data for prediction of additional 
samples. Discriminatory variables were identified by calculating the average of the variable 
importance (VIP) scores of the ensemble of models. A VIP cut-off of 1.5 was used to identify 
the most important variables driving the separation between classes and, hence, the metabolites 
with significant differences between the diseases. The fold changes of these variables were 
further investigated by analysis-of-variance (ANOVA) followed by Tukey’s honest significant 
difference (HSD) post-hoc test. The p-values obtained were then corrected for multiple 
comparisons using the Bonferroni correction. To assess if the OPLS-DA was able to identify 
AQP4-Ab NMOSD plasma with low/negative antibody levels at the time of sampling, a single 
predictive model was trained using the RRMS (n = 29)_and high titre (≥200) AQP4-Ab 
NMOSD (n = 25) plasma spectra (following successful validation using the method described 
in stage 1). This predictive model was subsequently tested using a completely independent 
naïve set of RRMS (n = 5) and AQP4-Ab NMOSD (n = 5) plasma samples from additional 
patients. These samples were not used in the model validation (stage 1). 
 
 
 
 
 
 
 
 
 
 
 
 Supplementary Fig. 1 Schematic representation of the statistical analysis scheme employed.   
 
 
 
 
 
 
 
 
 
 
 
 
 Supplementary Fig. 2 A representative OPLS-DA scores plot of RRMS (black) and AQP4-Ab NMOSD (red) 
spectra from patients not treated with steroids. The accuracy, specificity, and sensitivity of the ensemble of 
1000 models is significantly greater than random chance. P-values determined by the Kolmogorov-Smirnov 
test less than 0.001 are indicated by *** 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Fig. 3 A PCA scores plot of AQP4-Ab NMOSD plasma spectra. No clustering is observed as a 
result of antibody titre. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Fig. 4 OPLS-DA scores plots of AQP4-Ab NMOSD vs. (a) RRMS and (b) MOG-
Ab disease. There is no clustering due to EDSS. High EDSS scores ≥ 6 (green) are spread 
throughout the groups with lower EDSS < 6 (blue) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Fig. 5 OPLS-DA scores plots of MOG-Ab disease vs. (a) AQP4-Ab NMOSD and 
(b) RRMS. There is no clustering of the MOG-Ab samples due to the semi-quantitative MOG-
ab visual immunofluorescence intensity scores (VIIS) at serum dilution 1:20. VIIS ≥ 4 (dark 
red), 3 ≤ VIIS < 4 (red), 2 ≤ VIIS < 3 (orange), and 1 ≤ VIIS < 2 (yellow) are spread throughout 
the MOG-Ab cluster. AQP4-Ab NMOSD and RRMS samples (unfilled circles) were all negative 
on the MOG-Ab assay. 
 
 
 
 
 
 
 
 
Supplementary Fig. 6 Box plots of spectral integral values of each metabolite with significant 
changes across groups identified by multivariate analysis.  
